Moderna (MRNA) to Announce Quarterly Earnings on Friday

Moderna (NASDAQ:MRNA) is anticipated to announce its Q2 2026 results before the market opens on Friday, July 31st. Analysts expect Moderna to announce earnings of ($2.00) per share and revenue of $103.0950 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Friday, July 31, 2026 at 8:00 AM ET.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The company had revenue of $389.00 million for the quarter, compared to the consensus estimate of $236.37 million. During the same period last year, the business posted ($2.52) earnings per share. The firm’s quarterly revenue was up 260.2% compared to the same quarter last year. On average, analysts expect Moderna to post $-6 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moderna Trading Down 1.8%

NASDAQ:MRNA opened at $57.02 on Friday. The company has a fifty day moving average of $58.42 and a 200 day moving average of $51.75. Moderna has a 52 week low of $22.28 and a 52 week high of $85.60. The company has a quick ratio of 2.35, a current ratio of 2.41 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $22.62 billion, a P/E ratio of -7.00 and a beta of 0.94.

Insider Buying and Selling at Moderna

In related news, insider Shannon Thyme Klinger sold 3,471 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the sale, the insider owned 67,468 shares in the company, valued at $3,373,400. This represents a 4.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Abbas Hussain sold 5,682 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $46.63, for a total value of $264,951.66. Following the transaction, the director directly owned 12,066 shares of the company’s stock, valued at approximately $562,637.58. This trade represents a 32.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,088 shares of company stock valued at $6,193,713 over the last ninety days. Company insiders own 10.80% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently added to or reduced their stakes in MRNA. Kintegral Advisory LLC bought a new position in Moderna in the 4th quarter valued at approximately $85,000. Intesa Sanpaolo Wealth Management bought a new position in Moderna during the 4th quarter valued at about $153,000. Brown Brothers Harriman & Co. boosted its holdings in shares of Moderna by 35.4% during the 4th quarter. Brown Brothers Harriman & Co. now owns 2,671 shares of the company’s stock valued at $79,000 after acquiring an additional 699 shares during the last quarter. Zions Bancorporation National Association UT raised its holdings in shares of Moderna by 2,805.3% during the fourth quarter. Zions Bancorporation National Association UT now owns 4,968 shares of the company’s stock valued at $147,000 after purchasing an additional 4,797 shares during the last quarter. Finally, State of Wyoming lifted its position in Moderna by 43.6% during the fourth quarter. State of Wyoming now owns 3,032 shares of the company’s stock valued at $89,000 after purchasing an additional 920 shares during the period. 75.33% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on MRNA. Morgan Stanley upped their target price on Moderna from $33.00 to $39.00 and gave the company an “equal weight” rating in a report on Wednesday, July 8th. Bank of America boosted their price objective on shares of Moderna from $34.00 to $38.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Royal Bank Of Canada upped their price objective on shares of Moderna from $38.00 to $45.00 and gave the stock a “sector perform” rating in a report on Tuesday, July 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research report on Friday, June 12th. Finally, Jefferies Financial Group reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, June 18th. Two analysts have rated the stock with a Buy rating, ten have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Reduce” and an average target price of $40.00.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.